Table 3.
CDA and MTHFR gene polymorphisms in relation to outcome and toxicity
| AA n = 22 |
CC n = 7 |
AC n = 8 |
TT n = 2 |
CC n = 6 |
CT n = 12 |
|
|---|---|---|---|---|---|---|
| Clinical parameter | ||||||
| OS (months) | 7.8 (SD 9.1) | 17.3 (SD 13.7) | 10.1 (SD 3.1) | 11.0 (SD 12.4) | 5.0 (SD 19.3) | 9.8 (SD 11.0) |
| TTP (months) | 5.5 (SD 12.9) | 9.0 (SD 8.6) | 6.8 (SD 2.0) | 10.5 (−) | 1.9 (SD 12.8) | 6.4 (SD 9.0) |
| PR/CR | n = 8 | n = 3 | n = 5 | n = 1 | n = 1 | n = 6 |
| RR (%) | 36 | 43 | 63 | 50 | 17 | 50 |
| Grade 3 toxicity | n = 12 (55%) | n = 4 (57%) | n = 5 (63%) | n = 1 (50%) | n = 3 (50%) | n = 6 (50%) |
| Grade 4 toxicity | – | – | N = 1 (13%) | – | – | – |
Polymorphisms in the gene for CDA were measured in 37 patients. The AA variant was found in 22 patients, the CC variant in 7 patients and AC variant in 8 patients. Polymorphisms in the gene for MTHFR were measured in 20 patients. The TT variant was found in 2 patients, the CC variant in 6 patients and CT variant in 12 patients
OS overall survival (median months), TTP time to progression (median months), RR response rate (%), PR partial response, CR complete response, SD standard deviation